RESUMEN
Antidepressant drugs are first-line treatment for panic disorder. Facilitation of 5-HT1A receptor-mediated neurotransmission in the dorsal periaqueductal gray (dPAG), a key panic-associated area, has been implicated in the panicolytic effect of the selective serotonin reuptake inhibitor fluoxetine. However, it is still unknown whether this mechanism accounts for the antipanic effect of other classes of antidepressants drugs (ADs) and whether the 5-HT interaction with 5-HT2C receptors in this midbrain area (which increases anxiety) is implicated in the anxiogenic effect caused by short-term treatment with ADs. The results showed that previous injection of the 5-HT1A receptor antagonist WAY-100635 in the dPAG blocked the panicolytic-like effect caused by chronic systemic administration of the tricyclic AD imipramine in male Wistar rats tested in the elevated T-maze. Neither chronic treatment with imipramine nor fluoxetine changed the expression of 5-HT1A receptors in the dPAG. Treatment with these ADs also failed to significantly change ERK1/2 (extracellular-signal regulated kinase) phosphorylation level in this midbrain area. Blockade of 5-HT2C receptors in the dPAG with the 5-HT2C receptor antagonist SB-242084 did not change the anxiogenic effect caused by a single acute injection of fluoxetine or imipramine in the Vogel conflict test. These results reinforce the view that the facilitation of 5-HT1A receptor-mediated neurotransmission in the dPAG is a common mechanism involved in the panicolytic effect caused by chronic administration of ADs. On the other hand, the anxiogenic effect observed after short-term treatment with these drugs does not depend on 5-HT2C receptors located in the dPAG.
Asunto(s)
Antidepresivos/farmacología , Ansiedad/tratamiento farmacológico , Pánico/efectos de los fármacos , Sustancia Gris Periacueductal/efectos de los fármacos , Receptor de Serotonina 5-HT1A/fisiología , Receptor de Serotonina 5-HT2C/fisiología , Aminopiridinas/farmacología , Animales , Western Blotting , Prueba de Laberinto Elevado , Fluoxetina/farmacología , Imipramina/farmacología , Indoles/farmacología , Masculino , Prueba de Campo Abierto/efectos de los fármacos , Sustancia Gris Periacueductal/metabolismo , Sustancia Gris Periacueductal/fisiología , Piperazinas/farmacología , Piridinas/farmacología , Ratas , Ratas Wistar , Receptor de Serotonina 5-HT1A/efectos de los fármacos , Receptor de Serotonina 5-HT1A/metabolismo , Receptor de Serotonina 5-HT2C/efectos de los fármacos , Receptor de Serotonina 5-HT2C/metabolismo , Antagonistas del Receptor de Serotonina 5-HT1/farmacologíaRESUMEN
A wealth of evidence indicates that changes in procedural parameters and/or environmental conditions may exert a remarkable influence on the basal expression of defensive behaviors in different animal tests of anxiety. The goal of the current study was to further investigate the influence of procedural factors upon inhibitory avoidance acquisition and escape expression of male Wistar rats exposed to the elevated T-maze. These responses have been related in terms of psychopathology to generalized anxiety and panic disorders, respectively. Our results showed that the expression of these behaviors is not affected by prior handling of the animals or by increasing the illumination level of the experimental room from 60 to 580lx. They also showed that enhancing the number of avoidance trials from 3 to 6 favors the acquisition of this behavior. Under this condition, both diazepam (2mg/kg) and clonazepam (1-4mg/kg) caused anxiolytic effects, but only the latter benzodiazepine impaired escape expression, a panicolytic-like effect. In animals exposed to the elevated T-maze whole apparatus 24h before the test, the anxiolytic effect of these drugs was canceled out, which is consistent with the one-trial tolerance phenomenon widely observed in the elevated plus-maze. This procedure, however, does not interfere with the anti-escape effect caused by clonazepam. These results suggest that a 6-trial avoidance learning protocol may be a useful measure for compensating possible individual differences in the acquisition of this defensive response and to improve drug detection in the test.
Asunto(s)
Reacción de Prevención , Reacción de Fuga , Manejo Psicológico , Animales , Ansiolíticos/farmacología , Ansiedad/psicología , Reacción de Prevención/efectos de los fármacos , Clonazepam/farmacología , Diazepam/farmacología , Reacción de Fuga/efectos de los fármacos , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Modelos Psicológicos , Actividad Motora/efectos de los fármacos , Ratas , Ratas WistarRESUMEN
Changes in brain-derived neurotrophic factor (BDNF)-mediated signaling in the hippocampus have been implicated in the etiology of depression and in the mode of action of antidepressant drugs. There is also evidence from animal studies to suggest that BDNF-induced changes in the hippocampus may play a role in another stress-related pathology: anxiety. However, it is still unknown whether this neurotrophin plays a differential role in defensive responses associated with distinguished subtypes of anxiety disorders found in the clinic, such as generalized anxiety and panic disorder. In the present study, we investigated the effect of an acute BDNF injection into the rat dorsal hippocampus (DH) on inhibitory avoidance acquisition and escape expression measured in the elevated T-maze (ETM). We also assessed whether serotonergic neurotransmission may account for such effects. Intra-DH BDNF injection (200 pg) facilitated inhibitory avoidance in ETM. BDNF was equally anxiogenic in the light/dark transition test. Preadministration of the 5-HT1A receptor antagonist WAY-100635 fully counteracted the anxiogenic effect of BDNF in both tests. Intra-DH midazolam administration (10 nmol) impaired avoidance acquisition in ETM, suggesting an anxiolytic effect. Therefore, in the DH, facilitation of BDNF signaling seems to enhance 5-HT1A receptor-mediated neurotransmission to exert an anxiogenic effect associated with generalized anxiety.
Asunto(s)
Ansiedad/psicología , Mecanismos de Defensa , Hipocampo/efectos de los fármacos , Pánico , Receptor de Serotonina 5-HT1A/fisiología , Animales , Factor Neurotrófico Derivado del Encéfalo/farmacología , Masculino , Aprendizaje por Laberinto , Midazolam/farmacología , Piperazinas/farmacología , Piridinas/farmacología , Ratas , Ratas WistarRESUMEN
Chronic administration of antidepressants such as fluoxetine and imipramine increases the responsiveness of 5-HT(1A) receptors in dorsal periaqueductal grey matter (DPAG), a midbrain area consistently implicated in the pathogenesis of panic disorder. This effect has been related to the clinically relevant anti-panic action of these drugs. In this study we determined whether long-term administration of fluoxetine also affects 5-HT efflux in DPAG. As a comparison, the effect of chronic treatment with the anxiolytic 5-HT(1A) receptor agonist buspirone on DPAG 5-HT levels was assessed. We also investigated whether the inhibitory effect of chronic fluoxetine on escape behaviour in the rat elevated T-maze, considered as a panicolytic-like effect, is counteracted by intra-DPAG injection of the 5-HT(1A) receptor antagonist WAY 100635. Male Wistar rats were treated (1 or 21 d, i.p.) with fluoxetine, buspirone or vehicle, once daily. After treatment, 5-HT in DPAG was measured by in-vivo microdialysis coupled to HPLC. In another study, rats treated (21 d, i.p.) with either fluoxetine or vehicle also received intra-DPAG injection of WAY 100635 or saline 10 min before being tested in the elevated T-maze. Chronic, but not acute, administration of fluoxetine significantly raised extracellular levels of 5-HT in DPAG. Long-term treatment with buspirone was ineffective. In the elevated T-maze, intra-DPAG injection of WAY 100635 fully blocked the anti-escape effect of chronic administration of fluoxetine. Therefore, chronic fluoxetine facilitates 5-HT(1A)-mediated neurotransmission within DPAG and this effect accounts for the panicolytic-like effect of this antidepressant in the elevated T-maze.